Itraconazole

證據等級: L5

預測適應症: 10 個

Itraconazole: From Systemic Fungal Infections to Pneumocystosis

One-Sentence Summary

Itraconazole is a broad-spectrum triazole antifungal used globally for systemic fungal infections including aspergillosis, histoplasmosis, and candidiasis, but is currently not registered in Australia (no ARTG entries). The TxGNN model predicts it may be effective for Pneumocystosis (Pneumocystis jirovecii pneumonia, PCP), with 0 clinical trials and 20 publications available — however, all publications provide indirect rather than direct evidence for this indication.

Quick Overview

Item	Content
Original Indication	Not registered in Australia; globally used for systemic fungal infections (aspergillosis, histoplasmosis, onychomycosis, candidiasis)
Predicted New Indication	Pneumocystosis (Pneumocystis jirovecii pneumonia)
TxGNN Prediction Score	99.34%
Evidence Level	L4
Australia Market Status	Not marketed in Australia
Number of ARTG Entries	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Itraconazole is a triazole antifungal that works by inhibiting the fungal enzyme CYP51 (lanosterol 14α-demethylase), which blocks ergosterol biosynthesis and disrupts cell membrane integrity. This mechanism is highly effective against fungi whose membranes are predominantly composed of ergosterol — such as Aspergillus species, Histoplasma capsulatum, and Cryptococcus neoformans. Its broad-spectrum activity across diverse fungal pathogens makes it a logical candidate for knowledge-graph-based repurposing predictions.

However, the mechanistic basis for treating PCP with itraconazole is weak. Pneumocystis jirovecii has an unusual cell membrane composition with very low ergosterol content, and its CYP51 enzyme is structurally insensitive to azole-class drugs. A key 2003 molecular biology study (PMID 12606318) cloned the P. carinii Erg11 gene and identified structural differences at known azole-resistance sites — providing a clear biological explanation for why itraconazole lacks clinically meaningful activity against Pneumocystis in practice.

The TxGNN high score (0.993) most likely reflects knowledge-graph co-associations between PCP and other fungal infections in immunocompromised patients, rather than direct pharmacological evidence. PCP frequently co-occurs with invasive fungal infections that itraconazole does treat, creating indirect graph-level connections that do not translate into clinical efficacy. Standard first-line treatment for PCP remains trimethoprim-sulfamethoxazole (TMP-SMX), and no guideline recommends azole antifungals as primary or salvage therapy for this indication.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
11737382	2001	RCT	HIV Medicine	Phase III double-blind RCT of itraconazole prophylaxis against deep fungal infections in HIV-immunocompromised patients (n not specified for PCP arm); primary endpoint was invasive fungal disease prevention — PCP was not the target; does not support itraconazole for PCP
12606318	2003	Basic Science	Am J Respir Cell Mol Biol	Molecular characterisation of lanosterol 14α-demethylase (Erg11) from P. carinii; identified structural differences at 2 of 13 azole-resistance sites — provides direct mechanistic evidence for intrinsic azole insensitivity in Pneumocystis
21418688	2010	Guideline/Review	BMJ Clinical Evidence	HIV opportunistic infection prophylaxis guidelines; TMP-SMX confirmed as first-line for PCP prophylaxis and treatment; itraconazole not listed as an option for PCP
2121456	1990	Review	Drugs	Comprehensive review of therapy and prophylaxis for systemic protozoan infections including P. carinii; covers MOA, dosing, and efficacy but focuses on non-azole agents
36891307	2023	Case Report	Front Immunol	Talaromyces marneffei + P. jirovecii co-infection in a child with STAT1 mutation; itraconazole was used for the talaromycosis component only — indirect association with PCP context
30429396	2018	Observational	Indian J Med Microbiol	Retrospective study of respiratory fungal pathogens in immunocompetent vs. immunocompromised hosts; PCP discussed as background pathogen alongside invasive moulds and yeasts treated with itraconazole
8016481	1993	Review	Semin Respir Infect	Post-lung transplant infection management review; PCP discussed in context of prophylaxis strategies — itraconazole mentioned for other fungal pathogens, not for PCP
8397916	1993	Review	Curr Clin Top Infect Dis	BMT infection prophylaxis review; itraconazole discussed as antifungal prophylaxis agent; PCP prevention addressed separately with TMP-SMX — no mechanistic or clinical link between itraconazole and PCP
26036497	2015	Retrospective Cohort	Transplant Proc	Invasive fungal infections in kidney transplant recipients; PCP listed as co-morbidity background; itraconazole used for other fungal pathogens in this cohort
8967681	1996	Case Report	Ann Intern Med	Uveitis associated with rifabutin prophylaxis and concurrent itraconazole therapy in an HIV patient with a history of PCP; highlights a drug-drug interaction, not itraconazole efficacy for PCP

Australia Market Information

Itraconazole (DrugBank ID: DB01167) has no current ARTG registration in Australia. As at the data cut-off (22 June 2026), the drug is not marketed in Australia, with zero ARTG entries recorded.

For reference purposes, itraconazole is registered in comparable markets including the United States (FDA), the European Union (EMA), and New Zealand (Medsafe), where it is approved for systemic fungal infections such as aspergillosis, histoplasmosis, blastomycosis, and onychomycosis.

Clinicians requiring current safety and prescribing information should consult international Product Information documents (e.g., FDA label or EMA SmPC) or liaise with a clinical pharmacist.

Safety Considerations

Please refer to the TGA-approved Product Information (PI) for safety information.

Note: No TGA-registered Product Information is currently available for itraconazole in Australia. Until Australian registration is obtained, clinicians should refer to international prescribing information and standard clinical pharmacy resources for guidance on dosing, contraindications, and drug interactions. Key considerations from international data include significant CYP3A4-mediated drug interactions, negative inotropic effects (contraindicated in ventricular dysfunction), and QTc prolongation risk with concomitant agents.

Conclusion and Next Steps

Decision: Hold

Rationale: The mechanistic basis for itraconazole in PCP is absent — P. jirovecii has very low ergosterol content and its CYP51 is structurally insensitive to azole-class drugs (confirmed molecularly, PMID 12606318). None of the 20 identified publications provide direct evidence of itraconazole efficacy in PCP, and the high TxGNN prediction score most likely reflects knowledge-graph co-morbidity associations rather than genuine pharmacological activity. The TxGNN prediction does not carry clinical translation value for this indication.

To proceed, the following would be needed:

Identification of an alternative pharmacological target in P. jirovecii that itraconazole could plausibly modulate beyond CYP51 ergosterol synthesis
Direct in vitro susceptibility testing of itraconazole against P. jirovecii under standardised conditions (acknowledging that P. jirovecii is notoriously difficult to culture)
A formal hypothesis-generating preclinical or computational mechanistic study before any clinical investigation could be justified
Review of whether TxGNN model architecture can be refined to down-weight co-morbidity-driven graph associations that do not reflect direct drug–pathogen pharmacology
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.